Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
The use of antibody-drug conjugates (ADCs) is expanding in several malignancies, including urothelial carcinoma where two of these medications have been approved for use and several others remain under study. ADCs act by binding to specific cell surface proteins, delivering anticancer agents directl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1069356/full |
| _version_ | 1828071826612289536 |
|---|---|
| author | Sarah E. Fenton Sarah E. Fenton David J. VanderWeele David J. VanderWeele |
| author_facet | Sarah E. Fenton Sarah E. Fenton David J. VanderWeele David J. VanderWeele |
| author_sort | Sarah E. Fenton |
| collection | DOAJ |
| description | The use of antibody-drug conjugates (ADCs) is expanding in several malignancies, including urothelial carcinoma where two of these medications have been approved for use and several others remain under study. ADCs act by binding to specific cell surface proteins, delivering anticancer agents directly to the target cells. Preclinical studies suggest that loss of these surface proteins alters sensitivity to therapy and expression of target proteins vary significantly based on the tumor subtype, prior therapies and other characteristics. However, use of biomarkers to predict treatment response have not been regularly included in clinical trials and clinician practice. In this review we summarize what is known about potential predictive biomarkers for ADCs in UC and discuss potential areas where use of biomarkers may improve patient care. |
| first_indexed | 2024-04-11T00:59:39Z |
| format | Article |
| id | doaj.art-4944e77143374393a3ef756178fc5b61 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T00:59:39Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4944e77143374393a3ef756178fc5b612023-01-04T18:05:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.10693561069356Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinomaSarah E. Fenton0Sarah E. Fenton1David J. VanderWeele2David J. VanderWeele3Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United StatesDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United StatesDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United StatesThe use of antibody-drug conjugates (ADCs) is expanding in several malignancies, including urothelial carcinoma where two of these medications have been approved for use and several others remain under study. ADCs act by binding to specific cell surface proteins, delivering anticancer agents directly to the target cells. Preclinical studies suggest that loss of these surface proteins alters sensitivity to therapy and expression of target proteins vary significantly based on the tumor subtype, prior therapies and other characteristics. However, use of biomarkers to predict treatment response have not been regularly included in clinical trials and clinician practice. In this review we summarize what is known about potential predictive biomarkers for ADCs in UC and discuss potential areas where use of biomarkers may improve patient care.https://www.frontiersin.org/articles/10.3389/fonc.2022.1069356/fullbiomarkerantibody-drug conjugate (ADC)urothelial carcinoma (UC)predictivebladder cancer |
| spellingShingle | Sarah E. Fenton Sarah E. Fenton David J. VanderWeele David J. VanderWeele Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma Frontiers in Oncology biomarker antibody-drug conjugate (ADC) urothelial carcinoma (UC) predictive bladder cancer |
| title | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| title_full | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| title_fullStr | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| title_full_unstemmed | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| title_short | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| title_sort | antibody drug conjugates and predictive biomarkers in advanced urothelial carcinoma |
| topic | biomarker antibody-drug conjugate (ADC) urothelial carcinoma (UC) predictive bladder cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1069356/full |
| work_keys_str_mv | AT sarahefenton antibodydrugconjugatesandpredictivebiomarkersinadvancedurothelialcarcinoma AT sarahefenton antibodydrugconjugatesandpredictivebiomarkersinadvancedurothelialcarcinoma AT davidjvanderweele antibodydrugconjugatesandpredictivebiomarkersinadvancedurothelialcarcinoma AT davidjvanderweele antibodydrugconjugatesandpredictivebiomarkersinadvancedurothelialcarcinoma |